Article Text

Download PDFPDF
Role of Adjuvant Hysterectomy in Management of High-Risk Gestational Trophoblastic Neoplasia
  1. Jing Fang, MD*,
  2. Shu Wang, MD, PhD,
  3. Xiaobing Han, MD, PhD*,
  4. Ruifang An, MD*,
  5. Weimin Wang, MD, PhD* and
  6. Yan Xue, MD, PhD*
  1. * Department of Obstetrics & Gynecology, First Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi; and
  2. Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, People’s Republic of China.
  1. Address correspondence and reprint requests to Xiaobing Han, MD, PhD, 277# West Yanta Rd., Xi’an Shaanxi, 710061 People’s Republic of China. E-mail: xiaobinghan{at}mail.xjtu.edu.cn; xiaobing_han@hotmail.com.

Abstract

Objectives The objectives of the study were to investigate the role of and indications for adjuvant hysterectomy in patients with high-risk gestational trophoblastic neoplasia.

Methods We retrospectively analyzed records of patients identified as having undergone adjuvant hysterectomy for high-risk gestational trophoblastic neoplasia at First Hospital of Xi’an Jiaotong University, Xi’an, China, between 1985 and 2005. Therapeutic response was defined as complete with normalization of human chorionic gonadotropin (hCG) concentration, partial response with a decrease of more than 50%, and no response with a decrease of 50% or less. Complete remission was defined as normal hCG at 3 consecutive weekly assays without clinical evidence of disease.

Results A total of 21 patients (72.4%) showed an initial therapeutic response after surgery and 8 (27.6%) had no response. The initial therapeutic response was complete in 8 patients (27.6%) and partial in 13 (44.8%). During follow-up of 6 to 168 months, all 21 patients with an initial response and 2 of 8 patients without an initial response ultimately achieved complete remission (23 of 29 patients, 79.3%). Three patients (10.3%) had recurrence after primary remission; 2 patients (6.90%) died. Metastases outside of lungs or pelvic organs, number of metastases, presurgery chemoresistance to multidrug regimens, especially with 2 or more failed protocols, were considered possible reasons for decreased effectiveness of hysterectomy.

Conclusions Our study suggests that timely adjuvant hysterectomy is likely to benefit cautiously selected patients with high-risk gestational trophoblastic neoplasia. Although preoperative metastases limited to pelvic organs or lungs should not be considered an absolute contraindication, adjuvant hysterectomy should generally not be performed in the presence of distant metastases beyond the pelvic organs and lungs.

  • Gestational trophoblastic neoplasia
  • High risk
  • Hysterectomy

Statistics from Altmetric.com

Footnotes

  • The authors declare that there are no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.